DE60238633D1 - Screening auf inhibitoren des eindringens von hepatitis-c-virus - Google Patents

Screening auf inhibitoren des eindringens von hepatitis-c-virus

Info

Publication number
DE60238633D1
DE60238633D1 DE60238633T DE60238633T DE60238633D1 DE 60238633 D1 DE60238633 D1 DE 60238633D1 DE 60238633 T DE60238633 T DE 60238633T DE 60238633 T DE60238633 T DE 60238633T DE 60238633 D1 DE60238633 D1 DE 60238633D1
Authority
DE
Germany
Prior art keywords
screening
methods
cell
hepatitis
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238633T
Other languages
German (de)
English (en)
Inventor
Riccardo Cortese
Elisa Scarselli
Alessandra Vitelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Application granted granted Critical
Publication of DE60238633D1 publication Critical patent/DE60238633D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60238633T 2001-11-09 2002-11-01 Screening auf inhibitoren des eindringens von hepatitis-c-virus Expired - Lifetime DE60238633D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34450401P 2001-11-09 2001-11-09
PCT/EP2002/012272 WO2003040726A2 (en) 2001-11-09 2002-11-01 Screening for hepatitis c virus entry inhibitors

Publications (1)

Publication Number Publication Date
DE60238633D1 true DE60238633D1 (de) 2011-01-27

Family

ID=23350803

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238633T Expired - Lifetime DE60238633D1 (de) 2001-11-09 2002-11-01 Screening auf inhibitoren des eindringens von hepatitis-c-virus

Country Status (7)

Country Link
US (1) US20050019751A1 (https=)
EP (1) EP1444523B1 (https=)
JP (1) JP2005509160A (https=)
AT (1) ATE491952T1 (https=)
CA (1) CA2465731A1 (https=)
DE (1) DE60238633D1 (https=)
WO (1) WO2003040726A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
AU2005262006B2 (en) * 2004-07-08 2011-01-27 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antigen binding proteins directed against scavenger receptor B1 that inhibit HCV replication
WO2006103493A1 (en) * 2005-03-29 2006-10-05 Epixis Methods for enhancing the potency of hcv neutralizing antibodies
EP1832283A1 (en) * 2006-03-09 2007-09-12 Cenix Bioscience GmbH Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
US20090324580A1 (en) 2006-03-09 2009-12-31 Cenix Bioscience Gmbh Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
US9052321B2 (en) * 2008-10-03 2015-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flavivirus-based system for production of hepatitis C virus (HCV)
WO2017081595A1 (en) * 2015-11-12 2017-05-18 Sabic Global Technologies B.V. Methods for producing aromatics and olefins
CN112121168B (zh) * 2020-04-09 2022-03-04 中国人民解放军军事科学院军事医学研究院 一种抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用
JP2025531751A (ja) * 2022-09-07 2025-09-25 ユナイテッド キングダム リサーチ アンド イノベーション 代謝関連疾患のための治療薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270939B (it) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
US5998141A (en) * 1997-07-10 1999-12-07 Millennium Pharmaceuticals, Inc. Intronic and polymorphic SR-BI nucleic acids and uses therefor

Also Published As

Publication number Publication date
US20050019751A1 (en) 2005-01-27
CA2465731A1 (en) 2003-05-15
JP2005509160A (ja) 2005-04-07
EP1444523A2 (en) 2004-08-11
WO2003040726A3 (en) 2003-12-18
WO2003040726A2 (en) 2003-05-15
ATE491952T1 (de) 2011-01-15
EP1444523B1 (en) 2010-12-15

Similar Documents

Publication Publication Date Title
ATE411030T1 (de) Phosphonatanaloga von hiv- integrasehemmerverbindungen
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
WO2007084413A3 (en) Methods for treating hepatitis c
BRPI0515596A (pt) composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
WO2009069095A3 (en) Antiviral nucleoside compounds
EA201690452A1 (ru) Ингибиторы полимеразы hcv
CY1113038T1 (el) Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινου
BR0113161A (pt) Arilóxi piperidinas não imidazóis
IS7533A (is) Lifrarbólgu C-veirutálmar
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
EA200900288A1 (ru) Вакцина
DE60238633D1 (de) Screening auf inhibitoren des eindringens von hepatitis-c-virus
ATE552347T1 (de) Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen
DE60039729D1 (de) N-(8,8,8-Trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol zur Behandlung von Hepatitis-Virus-Infektionen
DE60025744D1 (de) Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
WO2009067191A3 (en) Methods and compositions for the treatment of hepatitis c virus (hcv) infection
DK1480627T3 (da) Fremgangsmåder til mindskelse af angiogenese
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
WO2009069132A3 (en) Novel reverse transcriptase inhibitors
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
EA200401362A1 (ru) Антивирусная терапия, основанная на противодействии рнк
ATE329308T1 (de) Laden von software
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen

Legal Events

Date Code Title Description
R097 No opposition filed against granted patent, or epo opposition proceedings concluded without decision

Ref document number: 1444523

Country of ref document: EP

Effective date: 20110916

R082 Change of representative

Ref document number: 1444523

Country of ref document: EP

Representative=s name: DR. VOLKER VOSSIUS PATENT- UND RECHTSANWALTSKANZLE